Key result
Higher estimated visceral adipose tissue is linked to ~103% greater incident CVD risk.
Why the study?
Visceral adipose tissue may contribute to cardiovascular disease, but evidence in Latin America is limited.
Does higher estimated visceral adipose tissue increase the risk of incident cardiovascular disease in individuals without diabetes in Latin America?
Cohort (n=23,097)
Yes
Does higher estimated visceral adipose tissue increase the risk of incident cardiovascular disease in individuals without diabetes in Latin America?
Hazard Ratio: 2.03 (95% CI 1.48–2.79)
Absolute Event Rate: 5.5% vs 2.9%
p-value: p=<0.001
Higher estimated visceral adipose tissue is significantly associated with an increased risk of incident cardiovascular disease in Latin American adults without diabetes, suggesting that population-level VAT reduction could meaningfully lower regional CVD burden.
Supports VAT as a CVD risk marker in Latin American adults without diabetes; extends prior data but remains hypothesis-generating and should not yet change practice.
Background Visceral adipose tissue (VAT) may causally contribute to cardiovascular disease (CVD); however, evidence in Latin America is limited. Here, we evaluated the association between estimated VAT (eVAT) and incident CVD among individuals without diabetes and estimated its population-attributable fraction (PAF) using data from the Cohorts Consortium of Latin America and the Caribbean (CC-LAC). Methods We pooled data from 15 prospective cohorts across 7 countries (n = 23,097; 62% women [n = 14,383], median age 51 years). Baseline eVAT (in grams [g]) was estimated using the Metabolic Score for Visceral Fat (METS-VF) index, incorporating age, sex, an insulin resistance index, and waist-to-height ratio. The primary outcome was incident CVD events, including fatal and non-fatal outcomes. Cause-specific Cox proportional hazards models estimated adjusted hazard ratios (aHR). PAF estimates used scenario-based eVAT quartile reductions. Findings Over a median follow-up of 4 years (113,622 person-years), 436 participants (1.9%) experienced an incident CVD event (174 fatal; 262 non-fatal). Uniformly age- and sex-standardized incidence rates were 3.8 (95% CI: 3.5–4.2) per 1000 person-years. Each 100 g increase in eVAT was associated with a 4% higher CVD hazard (aHR 1.04, 1.03–1.06). Compared with Q1 (<735 g), those in Q3 (1069–1441 g) and Q4 (≥1441 g) had a higher CVD hazard (Q3 aHR: 1.78 [1.28–2.49]; Q4 aHR: 2.03 [1.48–2.79]; p-for-trend <0.001). Associations were stronger for non-fatal events. In PAF estimates, shifting individuals from Q4 to lower quartiles could prevent 8.8% (2.8%–14.7%) of CVD events over 10 years. Interpretation Higher eVAT was associated with increased CVD risk in Latin America, supporting the view that modest VAT reductions could decrease regional CVD burden. Funding CC-LAC was funded by the Wellcome Trust.
No takes yet. Share an insight, caveat, or question.
Torres-Chavez et al. (2026) conducted a cohort in Cardiovascular disease (n=23,097). Estimated visceral adipose tissue (eVAT) vs. Lowest quartile of eVAT (<735 g) was evaluated on Incident fatal and non-fatal cardiovascular disease events (aHR 2.03, 95% CI 1.48-2.79, p=<0.001). Higher estimated visceral adipose tissue was associated with an increased risk of incident cardiovascular disease, with individuals in the highest quartile having a 2.03-fold higher hazard compared to the lowest quartile.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: